Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic
Go back to Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic| (NASDAQ: DRTS) | Delayed: 13.24 +0.23 (1.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.01 | 52 Week High | $ | |||
| Open | $13.04 | 52 Week Low | $ | |||
| Day High | $13.51 | P/E | N/A | |||
| Day Low | $12.80 | EPS | $ | |||
| Volume | 456,518 | |||||
| (NASDAQ: DRTSW) | Delayed: 3.54 +0.24 (7.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.30 | 52 Week High | $ | |||
| Open | $3.45 | 52 Week Low | $ | |||
| Day High | $3.71 | P/E | N/A | |||
| Day Low | $3.45 | EPS | $ | |||
| Volume | 4,143 | |||||
